Fig. 3

A biomimetic adhesive polycaprolactone nanocamptothecin based on macrophage membranes for improved cancer-targeting efficiency and metastasis inhibition. A The diagram illustrates the procedure for preparing macrophage membrane-camouflaged polymeric nanotherapy (mSLP). Triple-negative breast cancer (TNBC) mouse models bearing 4T1 B–E and Py8119 tumors F–J were treated with NPs in vivo for antitumor activity. B Following different drug treatments, tumor progression curves in the 4T1 orthotopic tumor-bearing mouse model were analyzed (n = 8). C Mouse survival curves (n = 8) from different treatment groups. D The body weight of mice in each group was monitored (n = 8). (E) On tumor sections, H&E, Ki67, and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining was performed. F After different drug treatments, tumor progression curves are shown in the Py8119 orthotopic tumor-bearing mouse model (n = 8). G Each group's body weight (n = 8) was monitored. (H and I) A photograph and weight of excised tumors from each group at the study's end. J Tumor sections stained with H&E, Ki67, and TUNEL. Adapted with permission from ref [67]. Copyright (2023) Bioactive materials. DDAB, dimethyldioctadecylammonium bromide; DSPE-PEG_2k, 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol) 2000]; SLP, SN38 lipid nanoparticles; FITC, fluorescein isothiocyanate; TNBC, Triple-negative breast cancer; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling